Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era
| Autor: | Ferdinando Marandino, Giulia Piperno, Marcella Mottolese, Flavia Novelli, Simonetta Buglioni, Isabella Sperduti, Amina Vocaturo, A. M. Cianciulli, Raffaele Perrone Donnorso, Maria Benevolo, Roberta Merola |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Receptor ErbB-2 Concordance Biopsy Fine-Needle Chromogenic in situ hybridization Breast Neoplasms Antibodies Monoclonal Humanized Sensitivity and Specificity Immunoenzyme Techniques Breast cancer Trastuzumab Biopsy medicine Humans Prospective Studies CISH In Situ Hybridization In Situ Hybridization Fluorescence Retrospective Studies Histocytological Preparation Techniques Paraffin Embedding medicine.diagnostic_test business.industry Gene Amplification Antibodies Monoclonal medicine.disease Oncology Chromogenic Compounds Liquid-based cytology Female business Fluorescence in situ hybridization medicine.drug |
| Zdroj: | The oncologist. 11(8) |
| ISSN: | 1083-7159 |
| Popis: | Learning Objectives After completing this course, the reader will be able to: Explain the importance of an accurate evaluation of HER-2 status to select breast cancer patients for trastuzumab therapy.Describe the current methods that assess HER-2 status in breast cancer.Discuss the advantages and limits of the CISH method for the detection of HER-2/neu gene amplification in histology and ThinPrep®-processed breast cancer fine-needle aspirates. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com The increasing evidence of trastuzumab efficacy in breast cancer (BC) patients means that an accurate and reproducible evaluation of HER-2 statusis of paramount importance in histological and in cytological samples. Currently, the two main methods used to analyze HER-2 amplification or overexpression are fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Although the two methods are strongly correlated for histological tissue, the evaluation of tumor morphology through FISH may be difficult and fluorescence fades quickly. These limitations can be overcome by chromogenic in situ hybridization (CISH), which can visualize the amplification product along with morphological features. In view of this, in the present study, we analyzed the usefulness of CISH on formalin-fixed, paraffin-embedded (FFPE) BC specimens and investigated whether CISH can be a valid technique in the determination of HER-2 status for fine-needle aspirates (FNAs) processed by liquid-based cytology. The results we obtained in a retrospective series of 111 FFPE BC specimens demonstrated good concordance between CISH and IHC and between CISH and FISH. The former concordance was comparable with that observed between FISH and IHC. When CISH was applied to a prospective series of 53 FNAs, from surgically removed BC, our data showed evidence of a higher concordance of results between liquid-based cytology and the companion FFPE tissues using CISH rather than HercepTest™. Therefore, CISH analysis, which is avaluable and reproducible alternative to FISH for selecting breast cancer patients for trastuzumab therapy, can lower false-positive immunocytochemistry findings in ThinPrep®-processed FNAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text